search
Back to results

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

Primary Purpose

Hyperlipidemia, Dyslipidemia, Hypercholesterolemia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
torcetrapib/atorvastatin
simvastatin
Sponsored by
Pfizer
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperlipidemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: eligible for statin treatment for LDL cholesterol by NCEP guidelines Exclusion Criteria: Women who are pregnant or lactating, or planning to become pregnant. Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors. Subjects with significant liver or kidney disease or significant heart failure.

Sites / Locations

  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site

Outcomes

Primary Outcome Measures

Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.

Secondary Outcome Measures

Changes in other lipid parameters and other biomarkers.

Full Information

First Posted
December 19, 2005
Last Updated
November 20, 2007
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00267254
Brief Title
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
Official Title
A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2007
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Pfizer

4. Oversight

5. Study Description

Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.
Detailed Description
For additional information please call: 1-800-718-1021

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperlipidemia, Dyslipidemia, Hypercholesterolemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
640 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
torcetrapib/atorvastatin
Intervention Type
Drug
Intervention Name(s)
simvastatin
Primary Outcome Measure Information:
Title
Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
Secondary Outcome Measure Information:
Title
Changes in other lipid parameters and other biomarkers.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: eligible for statin treatment for LDL cholesterol by NCEP guidelines Exclusion Criteria: Women who are pregnant or lactating, or planning to become pregnant. Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors. Subjects with significant liver or kidney disease or significant heart failure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
Pfizer Investigational Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
Pfizer Investigational Site
City
Mesa
State/Province
Arizona
Country
United States
Facility Name
Pfizer Investigational Site
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
Pfizer Investigational Site
City
Tempe
State/Province
Arizona
Country
United States
Facility Name
Pfizer Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
Pfizer Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
Pfizer Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
Pfizer Investigational Site
City
Santa Rosa
State/Province
California
Country
United States
Facility Name
Pfizer Investigational Site
City
Boynton Beach
State/Province
Florida
Country
United States
Facility Name
Pfizer Investigational Site
City
Melbourne
State/Province
Florida
Country
United States
Facility Name
Pfizer Investigational Site
City
Merritt Island
State/Province
Florida
Country
United States
Facility Name
Pfizer Investigational Site
City
Palm Bay
State/Province
Florida
Country
United States
Facility Name
Pfizer Investigational Site
City
Safety Harbor
State/Province
Florida
Country
United States
Facility Name
Pfizer Investigational Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
Pfizer Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
Pfizer Investigational Site
City
Newton
State/Province
Kansas
Country
United States
Facility Name
Pfizer Investigational Site
City
Topeka
State/Province
Kansas
Country
United States
Facility Name
Pfizer Investigational Site
City
Wichita
State/Province
Kansas
Country
United States
Facility Name
Pfizer Investigational Site
City
Madisonville
State/Province
Kentucky
Country
United States
Facility Name
Pfizer Investigational Site
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
Pfizer Investigational Site
City
Ann Arbor
State/Province
Michigan
Country
United States
Facility Name
Pfizer Investigational Site
City
Canton
State/Province
Michigan
Country
United States
Facility Name
Pfizer Investigational Site
City
Portage
State/Province
Michigan
Country
United States
Facility Name
Pfizer Investigational Site
City
Troy
State/Province
Michigan
Country
United States
Facility Name
Pfizer Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
Pfizer Investigational Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
Pfizer Investigational Site
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
Pfizer Investigational Site
City
Butte
State/Province
Montana
Country
United States
Facility Name
Pfizer Investigational Site
City
Lincoln
State/Province
Nebraska
Country
United States
Facility Name
Pfizer Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
Pfizer Investigational Site
City
Concord
State/Province
New Hampshire
Country
United States
Facility Name
Pfizer Investigational Site
City
Trenton
State/Province
New Jersey
Country
United States
Facility Name
Pfizer Investigational Site
City
Cooperstown
State/Province
New York
Country
United States
Facility Name
Pfizer Investigational Site
City
East Syracuse
State/Province
New York
Country
United States
Facility Name
Pfizer Investigational Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
Pfizer Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
Pfizer Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
Pfizer Investigational Site
City
Clinton
State/Province
South Carolina
Country
United States
Facility Name
Pfizer Investigational Site
City
Cordova
State/Province
Tennessee
Country
United States
Facility Name
Pfizer Investigational Site
City
Memphis
State/Province
Tennessee
Country
United States
Facility Name
Pfizer Investigational Site
City
Milan
State/Province
Tennessee
Country
United States
Facility Name
Pfizer Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Pfizer Investigational Site
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
Pfizer Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Pfizer Investigational Site
City
Payson
State/Province
Utah
Country
United States
Facility Name
Pfizer Investigational Site
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
Pfizer Investigational Site
City
Norfolk
State/Province
Virginia
Country
United States
Facility Name
Pfizer Investigational Site
City
Milwaukee
State/Province
Wisconsin
Country
United States

12. IPD Sharing Statement

Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5091030&StudyName=A+Clinical+Trial+Comparing+Torcetrapib%2FAtorvastatin+To+Simvastatin+In+Subjects+With+High+Cholesterol%2E
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

We'll reach out to this number within 24 hrs